High-risk patients with left ventricular dysfunction fare as well, or better, without the support of a microaxial flow pump during complex PCI procedures than those provided with a microaxial flow ... MedTech Dive: J&J’s Impella heart pump shows no patient benefit in 2 trials Fierce Biotech: Johnson & Johnson’s Impella pumps miss the mark in 2 major coronary studies Two separate randomized trials of Johnson & Johnson’s miniaturized Impella heart pumps failed to illustrate the devices’ benefits, spanning specific cases in patients with blockages in their coronary ... Johnson & Johnson’s Impella pumps miss the mark in 2 major coronary studies The results challenge the rapid growth of Impella support during high-risk PCI.

Context Explanation

Investigators say a reckoning is needed. Yahoo Finance: Johnson & Johnson Cardiac Trial Data Refines Impella Role In MedTech Story Johnson & Johnson (NYSE:JNJ) reported results from the randomized STEMI DTU trial of its Impella CP device at ACC 2026. The study assessed use of Impella CP before coronary intervention in heart ...